Acute supra-therapeutic oral terbutaline administration has no ergogenic effect in non-asthmatic athletes

被引:0
|
作者
Anthony M. J. Sanchez
Fabio Borrani
Marie Amélie Le Fur
Anais Le Mieux
Virgile Lecoultre
Guillaume Py
Christophe Gernigon
Katia Collomp
Robin Candau
机构
[1] Université Montpellier Sud-de-France,Faculté des Sciences du Sport
[2] INRA,Department of Sport and Exercise Science
[3] UMR866-Dynamique Musculaire Et Métabolisme,Department of Physiology
[4] University of Auckland,Faculty of Sport and Physical Education Sciences
[5] University of Lausanne,Laboratoire CIAMS
[6] Southern France University of Montpellier,Département des Analyses
[7] Laboratory Epsylon,undefined
[8] Université Paris Sud-Université Orléans,undefined
[9] AFLD,undefined
来源
关键词
β; -Agonist; Doping; Force–velocity relationship; Endurance performance; Anaerobic performance; Healthy athletes;
D O I
暂无
中图分类号
学科分类号
摘要
This study aimed to investigate the effects on a possible improvement in aerobic and anaerobic performance of oral terbutaline (TER) at a supra-therapeutic dose in 7 healthy competitive male athletes. On day 1, ventilatory threshold, maximum oxygen uptake \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$ (\dot{V}O_{2\max }) $$\end{document} and corresponding power output were measured and used to determine the exercise load on days 2 and 3. On days 2 and 3, 8 mg of TER or placebo were orally administered in a double-blind process to athletes who rested for 3 h, and then performed a battery of tests including a force–velocity exercise test, running sprint and a maximal endurance cycling test at Δ50 % (50 % between VT and \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$ \dot{V}{\text{O}}_{2\max } $$\end{document}). Lactatemia, anaerobic parameters and endurance performance (\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$ \dot{V}{\text{O}}_{ 2} ,\dot{V}E $$\end{document} and time until exhaustion) were raised during the corresponding tests. We found that TER administration did not improve any of the parameters of aerobic performance (p > 0.05). In addition, no change in \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$ \dot{V}{\text{O}}_{2} $$\end{document} kinetic parameters was found with TER compared to placebo (p > 0.05). Moreover, no enhancement of the force–velocity relationship was observed during sprint exercises after TER intake (p > 0.05) and, on the contrary, maximal strength decreased significantly after TER intake (p < 0.05) but maximal power remained unchanged (p > 0.05). In conclusion, oral acute administration of TER at a supra-therapeutic dose seems to be without any relevant ergogenic effect on anaerobic and aerobic performances in healthy athletes. However, all participants experienced adverse side effects such as tremors.
引用
收藏
页码:411 / 418
页数:7
相关论文
共 13 条
  • [1] Acute supra-therapeutic oral terbutaline administration has no ergogenic effect in non-asthmatic athletes
    Sanchez, Anthony M. J.
    Borrani, Fabio
    Le Fur, Marie Amelie
    Le Mieux, Anais
    Lecoultre, Virgile
    Py, Guillaume
    Gernigon, Christophe
    Collomp, Katia
    Candau, Robin
    [J]. EUROPEAN JOURNAL OF APPLIED PHYSIOLOGY, 2013, 113 (02) : 411 - 418
  • [2] Acute formoterol administration has no ergogenic effect in nonasthmatic athletes
    Stewart, IB
    Labreche, JM
    McKenzie, DC
    [J]. MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, 2002, 34 (02): : 213 - 217
  • [3] Ergogenic Effects of Inhaled β2-Agonists in Non-Asthmatic Athletes
    Wolfarth, Bernd
    Wuestenfeld, Jan C.
    Kindermann, Wilfried
    [J]. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2010, 39 (01) : 75 - +
  • [4] Montelukast does not have any ergogenic effects in non-asthmatic elite athletes.
    Sue-Chu, M
    Sandsund, M
    Reinertsen, R
    Bjermer, L
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 159 (03) : A640 - A640
  • [5] Effect of acute and short-term oral salbutamol treatments on maximal power output in non-asthmatic athletes
    Sanchez, Anthony M. J.
    Collomp, Katia
    Carra, Juliette
    Borrani, Fabio
    Coste, Olivier
    Prefaut, Christian
    Candau, Robin
    [J]. EUROPEAN JOURNAL OF APPLIED PHYSIOLOGY, 2012, 112 (09) : 3251 - 3258
  • [6] Effect of acute and short-term oral salbutamol treatments on maximal power output in non-asthmatic athletes
    Anthony M. J. Sanchez
    Katia Collomp
    Juliette Carra
    Fabio Borrani
    Olivier Coste
    Christian Préfaut
    Robin Candau
    [J]. European Journal of Applied Physiology, 2012, 112 : 3251 - 3258
  • [7] Do inhaled β2-agonists have an ergogenic potential in non-asthmatic competitive athletes?
    Kindermann, Wilfried
    [J]. SPORTS MEDICINE, 2007, 37 (02) : 95 - 102
  • [8] Do Inhaled B2-Agonists have an Ergogenic Potential in Non-Asthmatic Competitive Athletes?
    Wilfried Kindermann
    [J]. Sports Medicine, 2007, 37 : 95 - 102
  • [9] Is oral albuterol effective for acute cough in non-asthmatic children?
    Bernard, DW
    Goepp, JG
    Duggan, AK
    Serwint, JR
    Rowe, PC
    [J]. ACTA PAEDIATRICA, 1999, 88 (04) : 465 - 467
  • [10] ARE ORAL STEROIDS EFFECTIVE IN TREATING THE SYMPTOMS OF ACUTE LOWER RESPIRATORY TRACT INFECTION IN NON-ASTHMATIC ADULTS? THE ORAL STEROIDS FOR ACUTE COUGH (OSAC) PLACEBO-CONTROLLED RANDOMISED TRIAL
    Hay, A. D.
    Downing, H. E.
    Brookes, S. T.
    Young, G.
    Harnden, A.
    Hollinghurst, S. P.
    Kendrick, D.
    Little, P.
    May, M. T.
    Moore, M. V.
    Orton, E.
    Wang, K.
    Thompson, M. J.
    [J]. THORAX, 2015, 70 : A50 - A50